Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 5/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592725 | 0.86 | CLK1 (0.37) | KITMAPK1MAP2K4CLK1DYRK1A | |
| SCHEMBL1593076 | 0.85 | TRPA1 (0.45) | KITMAPK1TRPA1MAP2K4DYRK1A | |
| SCHEMBL1593665 | 0.84 | MKNK1 (0.42) | KITMAP2K4CCNT1CCNA2CDK2 | |
| SCHEMBL1592857 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MAP2K4DYRK1ACSNK1D | |
| SCHEMBL1593552 | 0.84 | ADORA2A (0.46) | MAPK1MAP2K4ADORA2ACCNT1CCNA2 | |
| SCHEMBL1592841 | 0.84 | MAP2K4 (0.45) | KITMAPK1SMN1; SMN2TRPA1MAP2K4 | |
| SCHEMBL29930500 | 0.81 | DYRK1A (0.47) | KITMAPK1ALDH1A1DYRK1AADORA2A | |
| SCHEMBL31006253 | 0.76 | FLT3 (0.48) | DYRK1ARPS6KB1CSNK1DCDK2 | |
| SCHEMBL15824509 | 0.76 | MAPT (0.46) | KITMAPK1ALDH1A1SMN1; SMN2MAP2K4 | |
| SCHEMBL1591705 | 0.76 | PIM1 (0.38) | MAPK1DYRK1ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2935248-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2935248-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2935248-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014100620-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100620-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KIT 1/4885MAPK1 163/4885ALDH1A1 2054/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | KIT 1128/4885MAPK1 35/4885ALDH1A1 1210/4885 |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | KIT 1/4885MAPK1 163/4885ALDH1A1 2054/4885 |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KIT 1/4885MAPK1 163/4885ALDH1A1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.